Avanir's Generic Combo Successful in Alzheimer's Study
the Neurology Advisor take:
Avanir Pharmaceuticals says its generic combination drug, AVP-923, was successful in suppressing agitation in patients with Alzheimer’s disease in a phase II clinical trial.
The drug, which combines generic cough suppressant dextromethorphan and generic quinidine, used to control irregular heartbeats, is the same drug combo that the company used in its approval for Nuedexta as a treatment for uncontrolled outbursts of emotion seen in pseudobulbar effect.
In the 10-week, randomized, placebo-controlled clinical trial of AVP-923, significant reductions in agitation were observed by both the primary and secondary endpoints of the neuropsychiatric inventory (NPI). Reductions in agitation were observed in both stage 1 (p=0.0002) and stage 2 (p=0.021) of the Sequential Parallel Comparison study design.
Improvements in secondary endpoints included total NPI score (p=0.014), clinical global impression of change-agitation (p=0.0003) and measures of caregiver burden (p≤0.05). While AVP-923 was generally well-tolerated, the most common adverse reactions included falls, diarrhea and urinary tract infections.
Following the trial’s positive results, Avanir plans to request meetings with both the FDA and European Medicines Agency to discuss further use of dextromethorphan programs in clinical studies related to Alzheimer’s disease.
Still, there is some concern over the “new” drug, which actually combines two old ones. The FDA has been calling for more innovative therapies for the treatment of Alzheimer’s, and members of US Congress will likely balk if Avanir attempts to price the generic drug combo as a high-priced therapy.
Avanir skyrockets as its controversial generic combo claims a hit in PhII Alzheimer's study
Next Article in Neurodegenerative Diseases
Neurology Advisor Articles
- Multiple System Atrophy: A Common Form of Atypical Parkinsonism
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Oral Film Formulation of Clobazam Gets FDA Approval for LGS
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Biomarkers of Alzheimer Disease Observed in Down Syndrome
- Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration
- Approaches for Better Diagnosis of Pediatric Multiple Sclerosis
- Short Segment Sensory Nerve Stimulation Offers Potential Diagnostic Value for Ulnar Neuropathy
- Incidence of Guillain-Barré Syndrome Linked With Recent Bone, Digestive Organ Surgery
- Pharmacist-Led Effort Cuts Inappropriate Rx in Older Adults